Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.
Condition: Metastatic Castration-resistent Prostate Cancer Interventions: Drug: Docetaxel; Drug: Abiraterone Acetate or Enzalutamide Sponsor: National Cancer Institute, Naples Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Docetaxel | Hormonal Therapy | Hormones | Prostate Cancer | Research | Taxotere